The importance of the lexatumumab/BID interaction in human cancers was also reported in other papers, where lexatumumab induced apoptosis through the activation of BID in non-Hodgkin’s lymphoma [69], melanoma [70], and liver tumor cells [71]. Here, BID is linked to non-Hodgkin lymphoma.